Vote in the European Parliament

Laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006

Tiemo Wölken – After recital 3 – Am 377
Date: 10.04.2024·Reference: A9-0141/2024
Rapporteur: Tiemo Wölken

Overall Result

Rejected
  • 73 For
  • 504 Against
  • 15 Abstention
  • 113 Did not vote
Amendment— You are viewing a sub-vote (amendment) of the main vote.Amendment 377 · Tabled by The LeftView amendment at the EP ↗
Amendment wording

Tabled by Marina Mesure

Added: (3 a) Treating health as a commodity has proven to be both costly and inefficient, as pharmaceutical companies have not addressed the crucial issue of shortages of medicinal products, despite receiving windfall profits at the expense of European citizens' right to healthcare. Enhanced public control over medical research and medicines production is urgently needed to ensure that treatments are not developed according to their profitability, and are affordable for all patients.

Wording as published by the EP, in English. PE760.539

← Back to Main Vote
Status and procedure

Outcome as recorded by the European Parliament.

Vote held on
Latest recorded step
Committee stage · (32 days ago)
Next scheduled step
Plenary · (in 12 days)

Procedure timeline

2023/0131(COD) · COD

Recorded procedure activities. These do not establish whether a law has entered into force.

  1. Recorded: Referral36 days until the next step
  2. Recorded: Committee stage153 days until the next step
  3. Recorded: Plenary453 days until the next step
  4. Recorded: Negotiations274 days until the next step
  5. Recorded: Committee stage204 days until the next step
  6. Recorded: Referral4 days until the next step
  7. Latest recorded: Committee stage32 days since this step began
  8. Planned: Plenary
Recorded activities (26)
  1. Referral to committee
  2. Committee report tabled
  3. Committee amendments tabled
  4. Committee amendments tabled
  5. Committee amendments tabled
  6. Committee amendments tabled
  7. Committee amendments tabled
  8. Committee amendments tabled
  9. Committee amendments tabled
  10. Committee amendments tabled
  11. Committee opinion adopted
  12. Committee opinion adopted
  13. Committee opinion adopted
  14. Committee report adopted
  15. Tabling for plenary
  16. Parliament’s first-reading position with amendments
  17. Plenary debate
  18. Plenary vote
  19. Plenary vote results
  20. Interinstitutional negotiations
  21. Interinstitutional negotiations
  22. Interinstitutional negotiations
  23. Interinstitutional negotiations
  24. Provisional agreement approved in committee
  25. Referral to committee
  26. Committee report tabled
Scheduled activities (not confirmation of completion)
  1. Plenary debate
  2. Plenary vote
  3. Plenary vote

Procedure file (OEIL) · European Parliament data
Retrieved:

Sources

Data: EP Open Data API

What is this about?

  • Reform strengthens access to medicines in the EU.
  • EMA gains expanded powers for authorization and monitoring.
  • Focus on environmental sustainability and „One Health“ approach.
Source: AI Summary with Mistral

Vote by political group

How the political groups voted

Members

Showing 10 of 705

Vote Position
NameCountryGroupVote Position
SpainNI
For
ItalyS&D
For
PortugalNI
For
FranceS&D
For
ItalyS&D
For
FranceGUE/NGL
For
ItalyNI
For
FranceGUE/NGL
For
LatviaNI
For
ItalyS&D
For
Show more
Follow us on Instagram@checksomevotes@checksomevotes_en